Deucravacitinib for moderate to severe psoriasis in Italy
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Skin clinical trials.
This study looks at how well deucravacitinib works for people with moderate to severe plaque psoriasis in real-life settings in Italy. It follows patients who have already started the treatment to see how they are doing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have moderate to severe plaque psoriasis
- You started taking deucravacitinib alone (not with other psoriasis drugs) 4 to 8 weeks ago
- The treatment was prescribed according to standard care and Italian national health rules (AIFA)
- You are not in any other experimental study for psoriasis
- You can understand the study and sign a consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well deucravacitinib works for adults with moderate to severe plaque psoriasis in everyday medical practice. It helps doctors understand the real-world benefits of this treatment.
This trial tests an oral medication called deucravacitinib for people who have both psoriasis and eczema (or psoriasis that looks like eczema) on their skin. The goal is to see if it can help reduce the severity of their plaques and itch.
This study provides continued access to the medication deucravacitinib for people who have completed one of several earlier studies. It aims to offer ongoing treatment for conditions like lupus, Sjogren's syndrome, or psoriasis.
This study looks at how well two common plaque psoriasis medicines—deucravacitinib and apremilast—work in everyday care. It may help researchers understand which option performs better in real patients outside of a traditional drug trial.
This trial tests an oral medication called TQH3906 for people with moderate to severe plaque psoriasis. It aims to see if the drug can improve skin symptoms and is for adults who have not had enough success with other treatments.
This Phase 4 study tests whether deucravacitinib can improve psoriasis by correcting abnormal immune-cell signals seen in people with moderate-to-severe disease. It may help reduce symptoms and improve control of psoriasis, while researchers also track immune changes.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.